To evaluate TDO inhibition as a potential therapeutic strategy for PD, NTRC 3531‐0 and LM10 were evaluated in parallel in a rotenone‐induced mouse model of PD [26, 27, 28]. Here, TDO2 is linked to Parkinson disease.